Sonoma Biotherapeutics
Damian joined Sonoma Bio in 2021 with a diversity of experience in program and alliance management, strategic operations, and organizational development.
He was most recently at Astellas Gene Therapies (formerly Audentes Therapeutics) managing their gene therapy research portfolio and providing operational expertise to their Research and Tech Ops organizations. Prior to Astellas, Damian worked at 23andMe leading global cross-functional projects and partnerships in research, health product, and clinical trial solutions.
Damian earned his PhD in Genetic, Molecular, and Cellular Biology from the Keck School of Medicine of the University of Southern California and his BS in Biochemistry and Cell Biology from the University of California San Diego.
This person is not in the org chart
This person is not in any offices
Sonoma Biotherapeutics
1 followers
Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.